Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models

Reuters10-13

Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models

Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following the conference presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95887) on October 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575279406?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575279406","market":"us","top_or_hot":-1,"title":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following the conference presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95887) on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-13 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following the conference presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95887) on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL53R4yG:1","article_id":"2575279406","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575279406","pubTimestamp":1760358709,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models. Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATNM":"Actinium Pharmaceuticals, Inc."},"translate_title":"Actinium Pharmaceuticals公布了ATNM-400有希望的临床前数据，强调了耐药前列腺癌模型中的持久肿瘤控制","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNM":0.9},"content_text":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Highlighting Durable Tumor Control in Resistant Prostate Cancer Models\n    \n\n        Actinium Pharmaceuticals Inc. has announced that preclinical data for its novel antibody radioconjugate, ATNM-400, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, scheduled for October 23-25, 2025, in Carlsbad, California. ATNM-400 is a first-in-class therapy armed with the alpha-emitter Actinium-225 and targets a non-PSMA antigen associated with prostate cancer progression. Preclinical studies have shown that ATNM-400 induces durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including those resistant to standard-of-care therapies such as enzalutamide and 177Lu-PSMA-617. The company reports that ATNM-400 demonstrated efficacy independent of PSMA expression levels and outperformed current therapies in preclinical models. The results will be made available online following the conference presentation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95887) on October 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575279406","isCrawlerRequest":true}